H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat
This article was originally published in The Pink Sheet Daily
Executive Summary
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
You may also be interested in...
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.
Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle
Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.